Skip to content

Study · Case report or series · n = 1 · 2026

2 results

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder.

Meilinger A, Campbell MA Jr, Reynolds HM, Chavez AS

Journal of primary care & community health1 Jan 2026

PMID41914511 (opens in a new tab)PMCIDPMC13039557 (opens in a new tab)DOI10.1177/21501319261437615 (opens in a new tab)PepBankPUB-41914511
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a man with obesity and alcohol use disorder, body weight decreased clinically significantly over 10 months of semaglutide.

    In plain wordsIn one man with obesity and heavy drinking, body weight fell clearly over 10 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · injectable · 10 monthsAs given in this study (human).

    Source sentences

    Summary
    Over the course of 10 months using an injectable GLP-1 RA (semaglutide), the patient showed a clinically significant decrease in both body weight and alcohol consumption.
    1 context sentence
    Summary · context
    A 34-year-old man was referred to a family medicine clinic for medication therapy management of obesity.
  2. 02HumanCase report or seriesEfficacy outcome

    In a man with obesity and alcohol use disorder, alcohol consumption decreased clinically significantly over 10 months of semaglutide.

    In plain wordsIn one man with obesity and heavy drinking, alcohol use fell clearly over 10 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseAlcohol consumption
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · injectable · 10 monthsAs given in this study (human).

    Source sentences

    Summary
    Over the course of 10 months using an injectable GLP-1 RA (semaglutide), the patient showed a clinically significant decrease in both body weight and alcohol consumption.
    2 context sentences
    Summary · context
    Although this patient initially sought care for weight loss goals to improve quality of life and symptoms of OSA, after 10 months of treatment with semaglutide he reported a considerable decrease in alcohol consumption leading to mental, social, and home life improvements.
    Summary · context
    A 34-year-old man was referred to a family medicine clinic for medication therapy management of obesity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.